FAXC interacts with ANXA2 and SRC in mitochondria and promotes tumorigenesis in cholangiocarcinoma

Author:

Fujimori Haruna1ORCID,Shima‐Nakamura Mao1,Kanno Shin‐Ichiro2,Shibuya‐Takahashi Rie1,Mochizuki Mai1,Mizuma Masamichi3,Unno Michiaki3ORCID,Wakui Yuta4,Abue Makoto4,Iwai Wataru4,Fukushi Daisuke5,Satoh Kennich5,Yamaguchi Kazunori6,Shindo Norihisa7,Yasuda Jun6,Tamai Keiichi1ORCID

Affiliation:

1. Division of Cancer Stem Cell Miyagi Cancer Center Research Institute Natori Japan

2. IDAC Fellow Research Group for DNA Repair and Dynamic Proteome Institute of Development, Aging and Cancer (IDAC) Tohoku University Sendai Japan

3. Department of Surgery Tohoku University Graduate School of Medicine Sendai Japan

4. Department of Gastroenterology Miyagi Cancer Center Natori Japan

5. Division of Gastroenterology Tohoku Medical and Pharmaceutical University Sendai Japan

6. Division of Molecular and Cellular Oncology Miyagi Cancer Center Research Institute Natori Japan

7. Cancer Chromosome Biology Unit Miyagi Cancer Center Research Institute Natori Japan

Abstract

AbstractCholangiocarcinoma (CCA) is one of the most difficult malignancies to treat as the therapeutic options are limited. Although several driver genes have been identified, most remain unknown. In this study, we identified a failed axon connection homolog (FAXC), whose function is unknown in mammals, by analyzing serially passaged CCA xenograft models. Knockdown of FAXC reduced subcutaneous tumorigenicity in mice. FAXC was bound to annexin A2 (ANXA2) and c‐SRC, which are tumor‐promoting genes. The FAXC/ANXA2/c‐SRC complex forms in the mitochondria. FAXC enhances SRC‐dependent ANXA2 phosphorylation at tyrosine‐24, and the C‐terminal amino acid residues (351–375) of FAXC are required for ANXA2 phosphorylation. Transcriptome data from a xenografted CCA cell line revealed that FAXC correlated with epithelial–mesenchymal transition, hypoxia, and KRAS signaling genes. Collectively, these findings advance our understanding of CCA tumorigenesis and provide candidate therapeutic targets.

Funder

Kobayashi Foundation for Cancer Research

Japan Society for the Promotion of Science

Takeda Medical Research Foundation

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3